Regulatory approval
Published by the Health Canada.
Health Canada approved pembrolizumab, in combination with chemotherapy with or without bevacizumab, for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.
This is written in the approval document as:
KEYTRUDA (pembrolizumab), in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD-L1 (CPS ≥ 1) as determined by a validated test.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Cervical Adenocarcinoma | Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Bevacizumab, Cisplatin, Paclitaxel, Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Cervical Adenocarcinoma | Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab | |
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Cervical Squamous Cell Carcinoma | Bevacizumab, Carboplatin, Paclitaxel, Pembrolizumab |